A New Artificial Urinary Sphincter with Conditional Occlusion for Stress Urinary Incontinence: Preliminary Clinical Results
|
|
- Morgan Baker
- 6 years ago
- Views:
Transcription
1 european urology xxx (2006) xxx xxx available at journal homepage: Ageing Male A New Artificial Urinary Sphincter with Conditional Occlusion for Stress Urinary Incontinence: Preliminary Clinical Results Sarah L. Knight a,, Judith Susser a, Tamsin Greenwell b, Anthony R. Mundy a,b, Michael D. Craggs a a Institute of Urology, Royal Free & University College Medical School, London, UK b Institute of Urology, Royal Free & University College London Hospitals Foundation Trust, London, UK Article info Article history: Accepted March 31, 2006 Published online ahead of print on May 2, 2006 Keywords: Artificial urinary sphincter Stress incontinence Post-prostatectomy Abstract Objectives: To perform a preliminary clinical investigation to determine the safety and efficacy of a novel artificial urinary sphincter (AUS) with conditional occlusion for the treatment of stress urinary incontinence. Methods: Male patients with urodynamically proven stress urinary incontinence after a prostatectomy were implanted with the novel AUS. They were followed up over a period of 12 months and the device tested for efficacy by using objective measurements of urinary leakage and continence. We derived a new measure for continence called the Continence Index. Results: We have demonstrated that the patients receiving the new AUS showed a reduction of greater than 10-fold in mean daily leakage volume from ml to 55.1 ml. There was an overall improvement in the Continence Index from 54% to 97%. Conclusions: The new AUS with conditional occlusion provides good continence rates and enables adjustment of regulating pressure in situ. # 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. 1. Introduction Hydraulically controlled artificial urinary sphincters (AUSs) have been used in the treatment of stress incontinence for nearly 30 years. The Brantley-Scott AUS was first introduced in 1973 [1] and has evolved into the current AS-800 (American Medical Systems Inc, USA), which until recently was the only commercially available device of this kind. Many studies have reported a good, long-term clinical Corresponding author. Institute of Urology, Royal Free & University College Medical School, 48 Riding House Street, London W1W 7EY, UK. Tel. +44 (0) ; Fax: +44 (0) address: s.l.knight@ucl.ac.uk (S.L. Knight). outcome of the AS-800 in various patient groups [2 4]. However, relatively high surgical revision rates up to 30% [5 7] have been reported. Revisions are the result of major complications including urethral erosion or atrophy (which may be attributed to high occlusion pressures), mechanical failures such as leaking connectors and infection leading invariably to removal of the whole or part of an implant. To address these problems, we designed, patented [8] and developed a new AUS. The new /$ see back matter # 2006 European Association of Urology. Published by Elsevier B.V. All rights reserved. doi: /j.eururo EURURO-1343; No of Pages 7
2 2 european urology xxx (2006) xxx xxx device incorporates many characteristics in common with the AS-800 device; however, it also includes a number of innovative features, which aim to overcome some of the disadvantages of the AS-800. The principal design features of the new implant include the following: A self-sealing port in the pump assembly for insitu pressure adjustment A stress relief mechanism providing low resting occlusion pressure and conditional occlusion of the urethra One-piece assembly to facilitate implantation and minimise mechanical failures Improved cuff design to reduce potential for creasing and fracture Patient-activated rapid cuff re-inflation facility The components of the new AUS are a stress r- elief balloon, a pressure-regulating balloon, a urethral occlusion cuff and a pump assembly unit (Fig. 1A and B). The stress relief balloon is placed extraperitoneally and transmits transient intra-abdominal pressure changes to the urethral cuff to increase occlusion pressure during periods of stress (conditional occlusion). The pressure-regulating balloon is identical to the stress relief balloon but determines the operating pressure of the device. The regulating pressure is adjustable in the range 0 80 cmh 2 O and can be altered by the injection or removal of fluid (on the basis of continence status) from the device in situ through the self-sealing port in the base of the pump assembly unit. A premoulded, adjustable circular urethral occlusion cuff m- inimises creasing and potential stress fractures, to reduce the possibility of leaking. The new device is manufactured as a single unit from medical-grade silicone rubber, sterilised with the use of gamma irradiation and supplied prefilled with sterile saline and ready for implantation. This paper describes the results of the 12-month preliminary clinical investigation (PCI) of the AUS, implanted at one centre (University College London Hospitals) in a group of male patients with urodynamically proven stress incontinence secondary to prostatectomy and pelvic trauma. 2. Patients and methods The new AUS has undergone extensive laboratory testing; a protocol for testing in patients was developed and approved by the UK Medicines and Healthcare products Regulatory Authority (MHRA) and local ethics committee for a PCI. The results of the PCI and the technical data formed the submission for CE approval, which has now been granted Patient selection The investigation was designed as a single-centre study, open to patients over the age of 18 years with urodynamically proven stress incontinence. The main exclusion criteria for the investigation were detrusor overactivity, previous radiation of the pelvis, previous implantation with an AUS, urinary tract infection and postresidual urine volume in excess of 50 ml. After obtaining informed consent, we recruited 11 male patients into the study, nine of whom (mean age, 66 years; range, 47 78) were found suitable to be implanted with the device and followed for a period of 12 months. Eight patients were incontinent after removal of the prostate and one after pelvic trauma. All patients had tried conservative treatment methods unsuccessfully, and three patients had undergone unsuccessful urethral-bulking procedures. All patients were relying on containment methods to manage their incontinence Assessment All patients were assessed before implantation and at 3, 6 and 12 months post-implantation. This included, urinalysis, a cystometrogram, flow rate, urethral pressure profiles, and completion of a 7-day voiding and leakage diary before each visit Urinalysis and culture A midstream urine sample was tested with the use of Multistix 8SG urine analysis dipsticks (Bayer plc, UK) and sent for culture if positive for leucocytes and nitrates, and treated accordingly Cystometry and flow rate Standard urodynamic equipment (Lectromed 3000, Lectromed, UK) was used to perform bladder filling and voiding cystometry. The bladder was filled via a urethral catheter by using sterile saline at room temperature at a fill rate of 60 ml/ min. Detrusor pressure was measured by subtraction and detrusor activity monitored for signs of over-activity. At full bladder capacity (V max ), filling was stopped, and patients were requested to initiate voiding; maximum flow rate (Q max ), volume voided (V v ) and residual volume were calculated Voiding diary Patients were required to complete a 7-day voiding and leakage diary before each visit. The diary included information on daily fluidintake(v i ),volumevoided(v v )andvolumeleaked(v l )either into pads or condom and leg bag. Patients were extensively educated on how to calculate leakage volume. Also, the total number of daily pads used was recorded when applicable. The diaries were analysed and a Continence Index calculated with the following formula and expressed as a percentage: Continence Index ¼ 100 V v ðv l þ V v Þ Urethral pressure profiles Urethral pressure profilometry (UPP), with cuff inflated and deflated, was carried out at 3 months by using the Brown- Wickham technique.
3 european urology xxx (2006) xxx xxx 3 Fig. 1 (A) The new artificial urinary sphincter with conditional occlusion showing individual components: (1) urethral occlusion cuff, (2) pressure-regulating balloon, (3) stress relief balloon, (4) pump and valve assembly unit with self-sealing port for pressurisation. (B) Operation of the new AUS: (1) The urethral occlusion cuff is deflated by squeezing the pump unit located in the scrotum, fluid is transferred to the pressure-regulating balloon and the patient can void through the empty cuff. (2) The cuff re-inflates through a slow return valve; rapid re-inflation can be achieved by squeezing the top of the pump unit. The cuff exerts sufficient pressure to maintain continence without compromising the urethral tissues. (3) During periods of raised intra-abdominal pressure, the fluid from the stress relief balloon is transferred to the cuff to provide additional pressure to maintain continence Implantation The new AUS was implanted as a one-piece, sterile device, prefilled to atmospheric pressure with sterile saline. Implantation was carried out under general anaesthesia in the lithotomy position with two incisions: one lower abdominal and one perineal. An indwelling catheter was placed in the urethra for guidance. The urethra was exposed through the perineal incision. A purpose-made disposable trocar was passed subcutaneously from the abdominal to the perineal incision and the cuff passed to the exposed urethral site. The adjustable cuff was positioned comfortably around the bulbar urethra so that it could be gently rotated and secured by a tape, glued with medical grade silicone adhesive and sutured in place for security. The stress relief balloon and regulating balloon were placed through the abdominal incision to sit extraperitoneally at the level of the bladder. The pump unit was then located in the scrotum. At implantation, the device was left at atmospheric pressure until therapeutic pressurisation after recovery from surgery Device pressurisation After the resolution of scrotal swelling and inflammation (approximately 2 4 weeks), patients were recalled to pressurise the AUS. The pressurisation procedure was carried out via the self-sealing port in the base of the pump under strict aseptic conditions. The concave base of the pump was palpated to locate the self-sealing port, which was inter-
4 4 Table 1 Individual patient average daily leakage volumes (in ml) and Continence Index (%) calculated from 7-day voiding diaries Patient no. Reason Average daily leakage volume (ml) Pre-operative Pressurisation 3-month 6-month 12-month Mean (SD) p value Mean (SD) p value Mean (SD) p value Mean (SD) p value Mean (SD) p value 002 TURP 605 (202) 333 (278) Patient removed from study 003 OP 334 (159) 151 (32) 100 (30) 110 (65) 85 (7) 004 TURP 697 (149) 224 (46) Patient removed from study 005 OP 2228 (1068) 0 (0) 0 (0) 0(0) 0 (0) 006 OP 678 (131) 188 (31) 151 (19) 95 (26) 71 (42) 007 OP 1101 (546) 15 (5) 27 (11) 17 (6) 009 OP 85 (30) 40 (9) 38 (27) 47 (46) 010 Trauma 011 OP 437 (136) 137 (45) 228 (5) 261 (74) 87 (22) Mean (SD) 770 (659) 207 (78) Patient no. Reason Average Continence Index (%) Pre-operative Pressurisation 3-month 6-month 12-month Pads Mean Pads Mean p value Pads Mean p value Pads Mean p value Pads Mean p value 002 TURP Patient removed from study 003 OP TURP Patient removed from study 005 OP OP OP OP Trauma OP (88) 88 (94) 51 (36) european urology xxx (2006) xxx xxx Mean (SD) (28.5) (9.1) (5.0) (2.4) SD = standard deviation; TURP = transurethral resection of the prostate; OP = open prostatectomy. p < 0.05, Statistical significance calculated by using two-tailed Student t test, compared with preoperative values. p < 0.01, Statistical significance calculated by using two-tailed Student t test, compared with preoperative values. p < 0.001, Statistical significance calculated by using two-tailed Student t test, compared with preoperative values.
5 european urology xxx (2006) xxx xxx 5 rogated percutaneously with a 23-G short needle. To increase the device pressure, we injected a known volume of sterile saline through the port to raise the pressure to a predetermined level. If necessary, additional fluid was added to optimise continence at a later date Data analysis Statistical comparisons were made with a paired, two-tailed Student t test with a significance level of p < 0.05 at the 95% confidence limit. 3. Results 3.1. Implantation Nine male patients were implanted with the device, and implantation and recovery were uneventful. The procedure was simplified because of the onepiece nature of the device and took minutes. Mean inpatient hospital stay was 4 days; all patients were discharged on demonstrating the ability to empty the bladder by either spontaneous voiding or intermittent catheterisation Device pressurisation Device pressurisation was carried out 2 4 weeks after implantation. In three patients, it was decided that pressurisation was unnecessary, as sufficient fluid had been replaced at implantation to provide satisfactory continence (005, 007, 010). Two patients underwent a single-device pressurisation (004, 009), and three patients underwent additional device pressurisations to further improve continence (003, 006, 011). Patients were instructed on how to operate the pump to deflate the cuff and enable voiding. Fig. 2 Bar chart showing mean (WSD) volume intake, voided and leakage over a 7-day period before implantation, after pressurisation and at follow-up investigations for all patients. Paired Student t test performed on leakage data; p < calculated for each patient (Table 1; Fig. 2) and a Continence Index derived. At each follow-up visit, all patients showed a statistically significant decrease in leakage volume after implantation of the new AUS. At 12 months post-implantation, there was an 85% reduction in the mean leakage volume from (659.7) ml to 51.7 (36.4) ml. Before implantation, there was a wide range in the mean Continence Index from 7.2% to 95.4%. Post-implantation all patients showed a statistically significant increase in the Continence Index at 3, 6 and 12 months (Table 1; Fig. 3). The mean Continence Index before implantation was 54.0%, which increased to 97.3% at the end of 12 months, representing an increase of almost 100%. Before implantation, five of the nine patients used pads to manage incontinence. However, at Cystometry and flow rates The implantation of the new AUS had no statistically significant effect on bladder capacity or flow rate. The mean (SD) pre-operative bladder capacity was (143.6) ml; at 12 months, it was (47.5). The mean pre-operative flow rate was 15.1 (7.4) ml/s; at 12 months, it was 22.2 (4.8) ml/s. None of the patients demonstrated bladder overactivity or any other adverse effect after AUS implantation Continence voiding diaries Eight of nine patients provided a satisfactory set of voiding diaries that could be analysed for each visit (patient 010 did not provide a complete set). The average volume intake (V i ), volume voided (V v ) and volume leaked (V l ) over the seven-diary period were Fig. 3 Continence Index derived from 7-day voiding diaries for all patients. Individual points represent mean (and SD) of Continence Index at pre-implantation, activation and postimplantation investigations for all patients. Paired Student t test; p < 0.01.
6 6 european urology xxx (2006) xxx xxx months, only three of the patients were still in the trial. Average pad usage in these patients changed from 3.3 per day to 1.6 per day at 12 months Urethral pressure profiles Urethral pressure profiles were carried out in seven patients. The intra-urethral cuff pressure was derived by taking the peak cuff pressure and subtracting the baseline urethral pressure. The mean (SD) intra-urethral cuff pressure measured post-implantation was 39.4 (14.7) cmh 2 O Adverse events Implants were removed in two patients; the first patient (002) never achieved satisfactory continence despite four pressurisation injections in the device. After magnetic resonance imaging (MRI) visualisation of the device, it was found that the cuff fixation had come undone and therefore no pressure was being applied to the urethra; the whole device was removed at the end of 8 weeks. The second patient (004) had satisfactory continence at the 3-month follow-up. He complained of sudden return of incontinence after lifting of heavy weight. The device was removed; on investigation it was discovered that there was a fracture at the joint between the tubing and the cuff. The manufacturing process has been changed subsequently to strengthen this joint. After these initial problems were rectified, there were no further adverse events associated with the new AUS. 4. Discussion The new AUS was developed to provide an alternative implantable device for effective control of stress incontinence. Nine male patients received the device and were followed for a minimum period of 12 months with the longest follow-up being 60 months. The results of the preliminary clinical investigation into the safety and efficacy of the device at the end of 12 months are reported in this paper. The implantation of the new AUS was quick and simple because of the one-piece assembly. This design minimised implant handling and priming time, and potentially reduced the risk of perioperative infection, improving overall implant survival time. Urethral erosion and atrophy are well-known problems associated with the use of artificial urinary sphincters; these problems have been attributed to the sustained high occlusion pressures exerted around the tissues of the urethra [9,10]. Previous studies have shown that pressures in excess of 40 cmh 2 O can compromise the blood perfusion in the urethra of healthy male volunteers [11]. The stress relief facility with conditional occlusion in the new AUS was designed to overcome the necessity of having sustained high urethral occlusion pressures to maintain continence. The stress relief balloon adds increased pressure to the urethral cuff in response to raised intra-abdominal pressures over and above the resting cuff pressure. This facility allows the device to be operated at a lower regulated pressure for the majority of the time, potentially reducing the incidence of urethral atrophy and erosion. The mean urethral pressure measured in the patients in this study was below 40 cmh 2 O. Longer-term studies will enable evaluation of this property more fully. The principal clinical outcome of the present study was continence. The most commonly used outcome measure in studies relating to the performance of the AUS devices is pad usage [2,3]. The type of pad used or criteria for changing were not clarified, making it an imprecise measure of continence. The Continence Index and leakage volumes described in the present study were derived from data collated from voiding diaries. This approach provided a more objective measure of clinical outcome after implantation of an AUS device. We have also recorded pad usage, but, as not all of the patients used pads to manage incontinence, the results of pad usage in the present study are not representative of the whole group. The mean Continence Index before implantation was 54.0%; at 12 months post-implantation, it was 97.3%, corresponding to an almost 100% improvement in the continence status of the patients with the new AUS. At 12-month follow-up, 83% of patients in the current study achieved a Continence Index greater than 97% and could be described as dry or substantially dry. These continence levels are similar to those reported with the AS-800 device [12] in which 73% of patients were dry or substantially dry and 88% showed improvement. The pressure in the new device was set 2 4 weeks post-operatively by injection of sterile saline into the self-sealing port in the base of the pump unit. Operating in the initial region of the pressurevolume curve of the regulating balloon, where pressure and volume are dependent, made it possible to adjust the pressure of the device by injection or removal of fluid. The device pressure can therefore be titrated against continence for each individual patient, removing the need to select a specific pressure range before operation. The device has the additional advantage of allowing this procedure to be
7 european urology xxx (2006) xxx xxx 7 repeated a number of times to optimise continence through the self-sealing port. The new artificial sphincter does not contain a radio-opaque solution and therefore cannot be imaged under plain X-ray radiography. However, use of MRI techniques has proved successful for viewing the device in situ [13]. The three-dimensional reconstruction also may be useful for determining the success of the design of the new cuff by enabling detailed imaging of its profile. The balloons also can be imaged by using ultrasound, and measurements can be taken to determine device pressure. The new cuff was moulded on a circular form to reduce potential stress fractures caused by creasing. Although at present this study is limited to the nine patients with the longest standing implant at 60 months, there have been no problems with failures of the cuff (excluding the patient whose cuff became undone because of improper fixation at surgery). 5. Conclusions We have described the preliminary clinical results of a new artificial urinary sphincter with conditional occlusion in the treatment of urodynamically proven stress incontinence in a group of male patients. The results show that this device can provide significant improvements in continence with an 85% reduction in leakage volumes and up to 100% improvement in the Continence Index. Implantation was quick and technically less demanding with no serious adverse events associated with the device. This new AUS provides adjustability in regulating pressure in situ, which may reduce the need for surgical revision. This preliminary study has shown significant improvements in continence in this group of patients. Now that CE mark approval has been granted, the device can be used more widely, allowing longer-term studies of efficacy and long-term survival, as well as comparison with other similar devices. Conflicts of interest This project was funded by the LINK Medical Implants Programme sponsored by the Department of Health and the Department of Trade & Industry, UK. It was carried out with two partners; Barloworld Scientific Limited, Stone, UK (who manufactured the implants) and Isotron plc, Swindon, UK (who sterilised the implants using gamma irradiation). References [1] Scott FB, Bradley WE, Timm GW. Treatment of urinary incontinence by an implantable prosthetic urinary sphincter. J Urol 1974;167: [2] Venn SN, Greenwell TJ, Mundy AR. The long-term outcome of artificial urinary sphincters. J Urol 2000;164: [3] Scott FB. The artificial urinary sphincter. Experience in adults. Urol Clin North Am 1989;16: [4] Hajivassiliou CA. The development and evolution of artificial urethral sphincters. J Med Eng Technol 1998; 22: [5] Hajivassiliou CA. A review of the complications and results of implantation of the AMS artificial urinary sphincter. Eur Urol 1999;35: [6] Maillet F, Buzelin J-M, Bouchot O, Karam G. Management of artificial urinary sphincter dysfunction. Eur Urol 2004;46: [7] Hussain M, Greenwell TJ, Venn SN, Mundy AR. The current role of the artificial urinary sphincter for the treatment of urinary incontinence. J Urol 2005;174: [8] Craggs MD, inventor. Prosthetic sphincter device. UK patent [135308] [9] Garcia-Montes F, Knight SL, Mundy AR, Craggs MD. The significance of low urethral blood flow in recurrent incontinence in patients with a long standing artificial urinary sphincter. Neurourol Urodyn 1999;18:394. [10] Hajivassiliou CA, Finlay IG. Uneven pressure application by the artificial urinary sphincter: an explanation for tissue ischaemia? BJU Int 1999;83: [11] Garcia-Montes F, Knight SL, Mundy AR, Craggs MD. Effects of artificial urinary sphincters on urethral blood perfusion measured with laser Doppler flowmetry. Eur Urol 1999; 35:16. [12] US Food and Drug Administration, Center for Devices and Radiological Health. AMS Sphincter 800 TM Urinary Prosthesis - P000053, summary of safety and effectiveness. Available from: [13] Deng J, Hall-Craggs MA, Craggs MD, et al. Three dimensional magnetic resonance imaging of the male urethrae with implanted artificial sphincters: initial results. Br J Radiol. In press.
MRI evaluation of the Flow-SecureTM artificial urinary sphincter.
MRI evaluation of the Flow-SecureTM artificial urinary sphincter. Poster No.: C-0793 Congress: ECR 2012 Type: Educational Exhibit Authors: G. Iglesias, A. Urresola Olabarrieta, B. Canteli Padilla, O. Cortazar
More informationFour-year follow-up on a Zephyr Surgical Implants 375 artificial urinary sphincter for male urinary incontinence from one urological centre in Poland
320 O R I G I N A L P A P E R FUNCTIONAL UROLOGY Four-year follow-up on a Zephyr Surgical Implants 375 artificial urinary sphincter for male urinary incontinence from one urological centre in Poland Ireneusz
More informationInformation for men considering a male sling procedure UHB is a no smoking Trust
Information for men considering a male sling procedure UHB is a no smoking Trust To see all of our current patient information leaflets please visit www.uhb.nhs.uk/patient-information-leaflets.htm Introduction
More informationCleveland Clinic Quarterly
Cleveland Clinic Quarterly Volume 31 JULY 1964 No. 3 A MEDICAL SILASTIC PROSTHESIS FOR THE CONTROL OF URINARY INCONTINENCE IN THE MALE A Preliminary Report J A M E S K. W A T K I N S, M. D., * R A L P
More informationManagement of Artificial Urinary Sphincter Dysfunction
European Urology European Urology 46 (2004) 241 246 Management of Artificial Urinary Sphincter Dysfunction Frédéric Maillet, Jean-Marie Buzelin, Olivier Bouchot, Georges Karam * Clinique Urologique, CHU
More informationI-STOP TOMS Transobturator Male Sling
I-STOP TOMS Transobturator Male Sling The CL Medical I-STOP TOMS sling for male stress urinary incontinence was developed in France where it is widely used and is the market leader. It is constructed with
More informationEuropean Urology 47 (2005)
European Urology European Urology 47 (2005) 209 213 The Comparison of Artificial Urinary Sphincter Implantation and Endourethral Macroplastique Injection for thetreatment of Postprostatectomy Incontinence
More informationSince the first published article, in 1974 by Scott et al on
Perineal Approach for Artificial Urinary Sphincter Implantation Appears to Control Male Stress Incontinence Better Than the Transscrotal Approach Gerard D. Henry,* Stephen M. Graham, Mario A. Cleves, Caroline
More informationAus Artificial Uretheral Sphincter Port System
NORFOLK VET PRODUCTS the AUS for the long-term relief of incontinence in dogs and cats making life easier for pets Speciality Medical Devices For The Veterinary Community the Aus Artificial Uretheral Sphincter
More informationAMS 800. Urinary Control System. User s Guide. Table of Contents. The AMS 800 Urinary Control System...1. Using the AMS 800 Urinary Control System...
AMS 800 Urinary Control System User s Guide Table of Contents The AMS 800 Urinary Control System...1 Using the AMS 800 Urinary Control System...2 Special precautions to take with your 800 before undergoing
More informationGlossary of terms Urinary Incontinence
Patient Information English Glossary of terms Urinary Incontinence Anaesthesia (general, spinal, or local) Before a procedure you will get medication to make sure that you don t feel pain. Under general
More information3. Urinary Catheters. Indications. Methods of Bladder Catheterization. Hashim Hashim
3. Urinary Catheters Hashim Hashim Indications Urinary catheters are used to drain urine from the bladder. The main indications are: A. Diagnostic Measure post-void residual in the absence of ultrasound
More informationBill Landry BScPT, BScH, MCPA, CAFCI Family Physiotherapy Centre of London
Bill Landry BScPT, BScH, MCPA, CAFCI blandry@fpclondon.com Family Physiotherapy Centre of London Objectives To describe the scope of post-prostatectomy incontinence To describe what s been done To provide
More informationA.M.I. ATOMS System. Hydraulic system substitutes urinary sphincter function in incontinent males
A.M.I. ATOMS System Product Group Urology Issue 11/2016 ATOMS = Adjustable TransObturator Male System Hydraulic system substitutes urinary sphincter function in incontinent males Long-term, adjustable
More informationNational Kidney and Urologic Diseases Information Clearinghouse
Urodynamic Testing National Kidney and Urologic Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is the urinary tract? The urinary tract
More informationManagement of Female Stress Incontinence
Management of Female Stress Incontinence Dr. Arvind Goyal Associate Professor (Urology& Renal Transplant) Dayanand Medical College & Hospital, Ludhiana, Punjab, India Stress Incontinence Involuntary loss
More informationCASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1
1 CASES FOR TRAINING OF THE INTERNATIONAL SPINAL CORD INJURY LOWER URINARY TRACT FUNCTION BASIC DATA SET CASE 1 35 years old man, who previously has been completely healthy, was shot twice in the neck
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Medical technology guidance SCOPE The UroLift system for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia 1
More informationUrinary Catheters. Prevalence of Infections
Urinary Catheterisation Urinary catheterisation is defined as an intervention to enable the emptying of the bladder by insertion of a catheter. Catheters can be short term less than 28 days or long term
More informationAMS 800 Urinary Control System
AMS 800 Urinary Control System 1 DAILY USE: While the cuff is closed, urine stays inside the bladder. To urinate, open the cuff as follows: Feel for the control pump in your scrotum. Stabilize the control
More informationUrodynamic Testing National Kidney and Urologic Diseases Information Clearinghouse
Urodynamic Testing National Kidney and Urologic Diseases Information Clearinghouse National Institute of Diabetes and Digestive and Kidney Diseases NATIONAL INSTITUTES OF HEALTH U.S. Department of Health
More informationLife after prostate cancer End your frustration. Restore your normalcy. Renew your confidence. Take the next step
Take the next step Visit EDCure.org to: Take the online ED quiz and get your customized treatment results Find an ED specialist in your area Register for free educational seminars to learn more about treatment
More informationAMS 800 Urinary Control System ACTIVATING:
AMS 800 Urinary Control System 1 ACTIVATING: Begin by stabilizing the control pump in the proper place by grasping the tubing above the control pump. Use your other hand to firmly squeeze the sides of
More informationIndwelling urinary catheter
Indwelling urinary catheter Information for patients and carers RDaSH leading the way with care What is a catheter? A catheter is a hollow flexible tube designed to drain urine from the bladder. Following
More informationP R E S E N T S Dr. Mufa T. Ghadiali is skilled in all aspects of General Surgery. His General Surgery Services include: General Surgery Advanced Laparoscopic Surgery Surgical Oncology Gastrointestinal
More informationUrogynaecology. Colm McAlinden
Urogynaecology Colm McAlinden Definitions Urinary incontinence compliant of any involuntary leakage of urine with many different causes Two main types: Stress Urge Definitions Nocturia: More than a single
More informationManagement of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction
Management of Post-Prostatectomy Urinary Incontinence and Sexual Dysfunction Robert C. Eyre, MD, FACS Associate Clinical Professor of Surgery (Urology) Harvard Medical School Post-prostatectomy Incontinence
More informationProcedure for removal and reinsertion of an indwelling urethral catheter (female)
Procedure for removal and reinsertion of an indwelling urethral catheter (female) Refer to National Infection Prevention and Control Manual for information on aseptic technique/cleaning equipment. Equipment
More informationNeurogenic Bladder: What You Should Know. A Guide for People with Spinal Cord Injury
Neurogenic Bladder: What You Should Know A Guide for People with Spinal Cord Injury Why Is This Information Important? Before SCI, you didn t have to think about managing your bladder After SCI, you may
More informationMedical Review Criteria Invasive Treatment for Urinary Incontinence
Medical Review Criteria Invasive Treatment for Urinary Incontinence Effective Date: December 21, 2016 Subject: Invasive Treatment for Urinary Incontinence Background: Urinary incontinence (the involuntary
More informationLoss of Bladder Control
BLADDER HEALTH: Surgery for Urinary Incontinence Loss of Bladder Control Surgery for Urinary Incontinence Don t Let Urinary Incontinence Keep You from Enjoying Life. What is Urinary Incontinence? What
More informationTHE ARTIFICIAL URINARY SPHINCTER:
THE ARTIFICIAL URINARY SPHINCTER: A TREATMENT FOR POST- PROSTATECTOMY URINARY INCONTINENCE Andrew L. Siegel, M.D. Board-Certified Urologist and Urological Surgeon Director: Center for Continence Care An
More informationLoss of Bladder Control
BLADDER HEALTH Loss of Bladder Control SURGERY TO TREAT URINARY INCONTINENCE AUA FOUNDATION OFFICIAL FOUNDATION OF THE AMERICAN UROLOGICAL ASSOCIATION What Is Urinary Incontinence? Urinary incontinence
More informationManagement of LUTS after TURP and MIT
Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent
More informationINCONTINENCE AND OTHER UROLOGICAL DILEMMAS DR. ANNA LAWRENCE UROLOGIST AUCKLAND HOSPITAL 161 UROLOGY
INCONTINENCE AND OTHER UROLOGICAL DILEMMAS DR. ANNA LAWRENCE UROLOGIST AUCKLAND HOSPITAL 161 UROLOGY COVERING INCONTINENCE BE ON JUST NAPPIES CATHETERS TYPES AVAILABLE AND WHEN TO USE THEM JJ STENTS???
More informationInjection of Urethral Bulking Agents
Injection of Urethral Bulking Agents Department of Gynaecology Patient Information What are urethral bulking agents? Urethral bulking agents are substances that are injected to support the bladder neck.
More informationIntermittent self-catheterisation (ISC) Information for patients Spinal Injuries
Intermittent self-catheterisation (ISC) Information for patients Spinal Injuries page 2 of 12 What is clean intermittent self-catheterisation (CISC)? Urinary catheterisation is a procedure used to drain
More informationINCONTINENCE. Continence and Pelvic Floor Rehabilitation TYPES OF INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE STRESS INCONTINENCE 11/08/2015
INCONTINENCE Continence and Pelvic Floor Rehabilitation Dr Irmina Nahon PhD Pelvic Floor Physiotherapist www.nahonpfed.com.au Defined as the accidental and inappropriate passage of urine or faeces (ICI
More informationHerefordshire Community Continence Appliances and Devices Formulary. Wye Valley NHS Trust 2018
Herefordshire Community Continence Appliances and Devices Formulary Wye Valley NHS Trust 2018 Contents Introduction... 2 1 Indwelling Urinary Catheters... 3 2 Catheter Valves... 5 3 Catheter Bags... 6
More informationStress Incontinence. Susannah Elvy Urogynaecology CNS
Stress Incontinence Susannah Elvy Urogynaecology CNS Definitions Prevalence Assessment Investigation Treatment Surgery Men International Continence Society define as the complaint of any involuntary leakage
More informationAdVance Male Sling System
AdVance Male Sling System Clinical study summary This document is a compilation and summary of several AdVance Male Sling System peer-reviewed journal articles. The information presented here is taken
More informationSuprapubic catheter insertion in the radiology department. Information for patients Urology
Suprapubic catheter insertion in the radiology department Information for patients Urology page 2 of 8 What is a suprapubic catheter? A suprapubic catheter is an indwelling tube that drains the bladder
More informationUrinary Incontinence
Urinary Incontinence Q: What is urinary incontinence and what causes it? A: When you are not able to hold your urine until you can get to a bathroom, you have what s called urinary incontinence (also called
More informationUrodynamic Tests. Department of Gynaecology. Patient Information
Urodynamic Tests Department of Gynaecology Patient Information What are urodynamic tests? Urodynamic tests assess the dynamic function of the lower urinary tract. The tests assess 3 functions; The ability
More informationTHE ACONTRACTILE BLADDER - FACT OR FICTION?
THE ACONTRACTILE BLADDER - FACT OR FICTION? Jacob Golomb Department of Urology Chaim Sheba Medical Center Tel Hashomer NEUROGENIC UNDERACTIVE DETRUSOR Central (complete/incomplete): Spinal cord injury-
More informationSurgery Illustrated Surgical Atlas The artificial genitourinary sphincter
BJUI BJU INTERNATIONAL Surgery Illustrated Surgical Atlas The artificial genitourinary sphincter John T. Stoffel and David M. Barrett Department of Urology, Lahey Clinic Medical Center, Burlington, USA
More informationTHE BULKING AGENT WITH LONG-LASTING EFFECT!
THE BULKING AGENT WITH LONG-LASTING EFFECT! Urogyn BV Transistorweg 5a 6534 AT Nijmegen The Netherlands t +31(0) 24 711 41 30 info@urogynbv.com www.urogynbv.com THE FIRST INJECTABLE IMPLANT THAT CAN COMPETE
More informationModule 5 Management Of Urinary Incontinence
Management Of Urinary Incontinence V3: Last Reviewed September 2017 Learning Outcomes Outline conservative management options Discover the options available to manage the different types of incontinence
More information6 Page Male Incontinence Booklet 10/09/ :44 Page 1. The Natural Non-Surgical Option for Male Urinary Incontinence
6 Page Male Incontinence Booklet /9/ :44 Page The Natural Non-Surgical Option for Male Urinary Incontinence 6 Page Male Incontinence Booklet /9/ :44 Page Stress Urinary Incontinence - A Stressful Prospect
More informationProcedure for removal and reinsertion of a supra pubic catheter
Procedure for removal and reinsertion of a supra pubic catheter Equipment required collect prior to procedure Perform this procedure as an aseptic technique to minimise the risk of introducing Clean the
More informationManaging urinary morbidity after brachytherapy. Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester
Managing urinary morbidity after brachytherapy Kieran O Flynn Department of Urology, Salford Royal Foundation Trust, Manchester Themes Can we predict urinary morbidity? Prevention of urinary morbidity
More informationLDR prostate brachytherapy
LDR prostate brachytherapy Introduction Low dose rate (LDR) prostate brachytherapy is a modern, effective minimally invasive treatment appropriate for many men with early prostate cancer. I perform this
More informationWest Yorkshire Major Trauma Network Clinical Guidelines 2015
WYMTN: Pelvic fracture with urogenital trauma KEY RECOMMENDATIONS 1. During the initial exploratory survey / secondary survey, a. The external urethral meatus and the transurethral bladder catheter (if
More informationIntravesical Botox Injections
Intravesical Botox Injections Department of Urology Patient Information What What is is Botox? Botox? Botox or Botulinum Type-A is toxin produced by bacteria called Clostridium Botulinum. It is given intravesically
More informationUrinary incontinence. Urology Department. Patient Information Leaflet
Urinary incontinence Urology Department Patient Information Leaflet Introduction This leaflet is for people who have been diagnosed with urinary incontinence. It contains information about the bladder,
More informationUrogynecology Associates of Philadelphia URODYNAMIC TESTING
URODYNAMIC TESTING Urogynecology Associates of Philadelphia Most women with urinary incontinence will need to complete a few simple tests, performed in the office, to help your doctor assess your symptoms
More informationBefore and After Your Surgery
UW MEDICINE PATIENT EDUCATION Before and After Your Surgery Artificial urinary sphincter or male urethral sling surgery This handout explains how to prepare for and what to expect after artificial urinary
More informationThis information is intended as an overview only
This information is intended as an overview only Please refer to the INSTRUCTIONS FOR USE included with this device for indications, contraindications, warnings, precautions and other important information
More informationOveractive bladder. Information for patients from Urogynaecology
Overactive bladder Information for patients from Urogynaecology An overactive bladder (OAB) is a very common problem. It can cause distressing symptoms that are difficult to control. These can include
More informationLife after prostate cancer. End your frustration. Restore your normalcy. Renew your confidence. Erectile dysfunction and male incontinence
Life after prostate cancer End your frustration. Restore your normalcy. Renew your confidence. Erectile dysfunction and male incontinence Welcome This brochure is designed to help you learn more about
More informationGUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION
GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E. Chartier-Kastler, G. Kramer, A. Mattiasson, J-J. Wyndaele Introduction NLUTD (neurogenic lower urinary
More informationMale and Female Catheterisation
Male and Female Catheterisation Practical Skills Teaching Year 3 Medical Students MB BCh 2012-2013 Contents Introduction to workshop... 3 Overall Session Aim... 4 Intended Learning Outcomes... 4 Workshop
More informationVictoria Frohna s mold story
Victoria Frohna s mold story January 2000 Discussion of the Artificial Urinary Sphincter (AUS) Dr. Charles Jennings Dr. Charles Jennings is a Diplomat with the American Board of Urology; a Member of the
More informationManaging your bladder with a Supra-pubic catheter at home
Managing your bladder with a Supra-pubic catheter at home Providing a range of NHS services in Gateshead, South Tyneside and Sunderland. Managing your bladder with a Supra-pubic catheter at home The purpose
More informationBladder dysfunction in ALD and AMN
Bladder dysfunction in ALD and AMN Sara Simeoni, MD Department of Uro-Neurology National Hospital for Neurology and Neurosurgery Queen Square, London 10:15 Dr Sara Simeoni- Bladder issues for AMN patients
More informationPolicy for Prostatism/Lower Urinary Tract Symptoms in men
NHS Halton Clinical Commissioning Group NHS Liverpool Clinical Commissioning Group NHS St Helens Clinical Commissioning Group NHS South Sefton Clinical Commissioning Group NHS Southport and Formby Clinical
More informationgentle catheter clip USER GUIDE optimum medical support optimummedical independence with confidence
independence with confidence optimum medical support Have you visited the patient support area of our website? Designed to fix and support urethral and suprapubic catheters at the catheter bifurcation
More informationClean Intermittent Self-Catheterisation (CISC)
Saint Mary s Hospital & Trafford General Hospital Uro-gynaecology Service Information for Patients Clean Intermittent Self-Catheterisation (CISC) What is catheterisation? Catheterisation involves passing
More informationBULKAMID STANDARD OPERATING PROCEDURE
BULKAMID STANDARD OPERATING PROCEDURE Contents 1 1 2 3-4 5-6 5-6 7 9-12 9 10 11 12 13 13 13 15 16 Products Bulkamid multiple use instruments Bulkamid single use instruments The Bulkamid system Pre-procedure
More informationTension-free Vaginal Tape (TVT)
Page 1 of 7 Tension-free Vaginal Tape (TVT) Introduction This leaflet will provide you with basic information about the Tension--free Vaginal Tape (TVT) procedure. What is a TVT? TVT is an operation to
More informationRecommandations de prise en charge des vessies neurogènes EAU 2006
Annexe 4-1 Recommandations de prise en charge des vessies neurogènes EAU 2006 (Version courte) 685 686 GUIDELINES ON NEUROGENIC LOWER URINARY TRACT DYSFUNCTION M. Stöhrer (chairman), D. Castro-Diaz, E.
More informationImpact of urethral catheterization on uroflow during pressure-flow study
Research Report Impact of urethral catheterization on uroflow during pressure-flow study Journal of International Medical Research 2016, Vol. 44(5) 1034 1039! The Author(s) 2016 Reprints and permissions:
More informationlimbsandthings.com Advanced Female Catheterisation Trainer User Guide For more skills training products visit Limbs & Things Ltd.
Advanced Female Catheterisation Trainer Product No: 60155 User Guide For more skills training products visit limbsandthings.com Limbs & Things Ltd. Sussex Street, St Philips Bristol, BS2 0RA, UK sales@limbsandthings.com
More informationIncontinence. Anatomy The human body has two kidneys. The kidneys continuously filter the blood and make urine.
Incontinence Introduction Urinary incontinence occurs when a person cannot control the emptying of his or her urinary bladder. It can happen to anyone, but is very common in older people. Urinary incontinence
More informationUrodynamic study before and after radical porstatectomy 가톨릭의대성바오로병원김현우
Urodynamic study before and after radical porstatectomy 가톨릭의대성바오로병원김현우 Introduction Radical prostatectomy - treatment of choice for patients with localized prostate cancer. Urinary incontinence and/or
More informationMale urinary incontinence: Artificial sphincter
GUIDELINES IN FOCUS Truzzi JC et al. Male urinary incontinence: Artificial sphincter Incontinência urinária masculina: Esfíncter artificial Authorship: Brazilian Society of Urology (SBU) Participants:
More informationGuidelines on Neurogenic Lower Urinary Tract Dysfunction
Guidelines on Neurogenic Lower Urinary Tract Dysfunction (Text update March 2009) M. Stöhrer (chairman), B. Blok, D. Castro-Diaz, E. Chartier- Kastler, P. Denys, G. Kramer, J. Pannek, G. del Popolo, P.
More informationTHE LONG-TERM SOLUTION FOR MALE INCONTINENCE
THE LONG-TERM SOLUTION FOR MALE INCONTINENCE Urogyn BV Transistorweg 5a 6534 AT Nijmegen The Netherlands t +31(0) 24 711 41 30 info@urogynbv.com www.urogynbv.com THE FIRST INJECTABLE IMPLANT THAT CAN COMPETE
More informationSacral Nerve Stimulation (SNS) System Implantation
Patient & Family Guide 2016 Sacral Nerve Stimulation (SNS) System Implantation www.nshealth.ca Sacral Nerve Stimulation (SNS) System Implantation SNS system implantation involves placing a lead ( leed,
More informationTOOKAD (padeliporfin) Patient Information Guide
TOOKAD (padeliporfin) Patient Information Guide TOOKAD is used to treat low-risk localized prostate cancer This medicine is subject to additional monitoring. This will allow quick identification of new
More informationCurrent Indications for the Use of The Artificial Genitourinary Sphincter and Management of It s Complications
Article TheScientificWorldJOURNAL (2004) 4 (S1), 114 127 ISSN 1537-744X; DOI 10.1100/tsw.2004.57 Current Indications for the Use of The Artificial Genitourinary Sphincter and Management of It s Complications
More informationPATIENT INFORMATION 2017 NeoTract, Inc. All rights reserved. Printed in the USA. MAC Rev A
PATIENT INFORMATION OVER 70% OF MEN IN THEIR 60s HAVE SYMPTOMS OF BPH 1 BPH affects more than 500 million men worldwide, with many men suffering from symptoms of enlarged prostate. 1 You no longer have
More informationInterventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566
Single-incision short sling mesh insertion for stress urinary incontinence in women Interventional procedures guidance Published: 12 October 2016 nice.org.uk/guidance/ipg566 Your responsibility This guidance
More informationW11: Basic Urodynamics - An Interactive Workshop Workshop Chair: Hashim Hashim, United Kingdom 06 October :00-17:00
W11: Basic Urodynamics - An Interactive Workshop Workshop Chair: Hashim Hashim, United Kingdom 06 October 2015 14:00-17:00 Start End Topic Speakers 14:00 14:15 Introduction Hashim Hashim 14:15 14:30 Physics
More informationDepartment of Urology, University Hospital Ulm, Prittwitzstrasse 43, D Ulm, Germany
International Scholarly Research Network ISRN Urology Volume 2012, Article ID 304205, 5 pages doi:10.5402/2012/304205 Clinical Study The Retrourethral Transobturator Sling Suspension in the Treatment of
More informationIndwelling Urinary Catheter Template for Care Plan Development Problem No: be a last resort when all suprapubic catheter in CAUTI
Indwelling Urinary Catheter Template for Care Plan Development Problem No: Name: DOB Address: Indwelling Urinary Catheter (Urethral/ Suprapubic) Date Assessed Need GOAL INTERVENTION Evaluation of intervention/
More informationIn addition to the indications stated above catheterisation may be carried out in female patients for two further reasons:
Urinary Catheterisation This is the process of inserting a specially designed tube into the urinary bladder using an aseptic technique, for the purpose of draining urine, removing clots and/or debris and
More informationEUROPEAN UROLOGY 57 (2010)
EUROPEAN UROLOGY 57 (2010) 430 436 available at www.sciencedirect.com journal homepage: www.europeanurology.com Surgery in Motion Transrectal Ultrasound Guided Implantation of Adjustable Continence Therapy
More informationThe number following the procedure code is the TRICARE payment group. KIDNEY
TRICARE/CHAMPUS POLICY MANUAL 6010.47-M JUNE 25, 1999 S POLICY CHAPTER 13 SECTION 9.1 ADDENDUM 1, SECTION 8 TRICARE-APPROVED AMBULATORY SURGERY S - URINARY SYSTEM The number following the procedure code
More informationOVER 70% OF MEN IN THEIR 60s HAVE SYMPTOMS OF BPH 1
PATIENT INFORMATION BPH affects more than 500 million men worldwide, with many men suffering from symptoms of enlarged prostate. 1 You no longer have to be one of them! OVER 70% OF MEN IN THEIR 60s HAVE
More informationTransurethral Resection of Prostate
Transurethral Resection of Prostate Information for Patients This leaflet explains: What does the procedure involve?...2 What are the alternatives to this procedure?...2 What should I expect before the
More informationLaser Prostatectomy Urology Patient information Leaflet
Laser Prostatectomy Urology Patient information Leaflet Page 1 Laser Prostatectomy Your surgeon has recommended that you have laser surgery to your prostate. We hope that this leaflet answers any questions
More informationTension Free vaginal tape. Mrs Ami Shukla, Consultant Urogynaecologist Northampton General Hospital Northampton NN1 5BD
Tension Free vaginal tape Mrs Ami Shukla, Consultant Urogynaecologist Northampton General Hospital Northampton NN1 5BD What is a TVT procedure? A TVT (Tension Free Vaginal Tape) procedure is an operation
More informationConclusions. Keywords
Functional Urology Outcomes of single- vs double-cuff artificial urinary sphincter insertion in low- and high-risk profile male patients with severe stress urinary incontinence Sascha A. Ahyai*, Tim A.
More informationAppendix F: Continence Care and Bowel Management Program Training Presentation. Audience: For Front-line Staff Release Date: December 22, 2010
Appendix F: Continence Care and Bowel Management Program Training Presentation Audience: For Front-line Staff Release Date: December 22, 2010 Objectives Address individual needs and preferences with respect
More informationUROLOGY SYDNEY Level 1, St George Medical Centre 1 South Street Kogarah NSW 2217 Ph: Fax:
Pre Operative care: Preop investigations: Radical Prostatectomy Pre and Post Operative Care Once your surgery date has been decided you will be sent for routine blood and urine tests, an ECG will also
More informationA Simple Solution. to a Common Problem. Find relief from sudden, unplanned urine leakage.
A Simple Solution to a Common Problem Find relief from sudden, unplanned urine leakage. A Common Problem Millions of women suffer from stress urinary incontinence (SUI). This condition results in accidental
More informationOveractive bladder syndrome (OAB)
Service: Urology Overactive bladder syndrome (OAB) Exceptional healthcare, personally delivered What is OAB? An overactive bladder or OAB is where a person regularly gets a sudden and compelling need or
More information